FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978219532> ?p ?o ?g. }

• W2978219532 endingPage "v647" @default.
• W2978219532 startingPage "v646" @default.
• W2978219532 abstract "Abstract Background The ModuLung trial addresses the medical need for low-toxic therapies in frequently comorbid patients with relapsed or refractory non-small cell lung cancer (NSCLC). We evaluated safety and efficacy of a biomodulatory approach in > =2nd-line, aiming for induction of anakoinosis i.e. communicative reprogramming of dysregulated cellular and intercellular homeostasis. Methods Patients with stage IIIB/IV squamous or non-squamous NSCLC and disease progression during or after at least one platinum-based chemotherapy were stratified according to histology, and randomly assigned 1:1 to treosulfan 250 mg twice daily, pioglitazone 45 mg once daily and clarithromycin 250 mg twice daily (experimental arm) or nivolumab 3 mg/kg every 2 weeks (control arm). The primary endpoint was progression-free survival (PFS). Results Due to the approval of checkpoint inhibitors in first-line, the study was prematurely closed after randomization of 40 of the 86 initially planned patients. The main efficacy and safety results are presented in the table and show no statistically significant difference between groups. The two-year survival rate achieved in the biomodulatory arm was 10% (95% CI, 1.2 to 31.7) and 5.9% (95% CI, 0.1 to 28.7) in the nivolumab arm. 75% and 53% of the patients proceeded to a further line of therapy, respectively. Table . 1570P Results Biomodulatory Arm (n = 20) 35% > 2nd-line Nivolumab Arm (n = 17) 41.2% > 2nd-line HR & 95% CI or p-value PFS, median in months 1.6 2.1 HR = 1.17; 95% CI, 0.59--2.34 OS, median in months 8.2 6.9 HR = 0.86; 95% CI, 0.38-1.96 ORR, n (%) 2 (10%) 0 (0%) P = 0.49 Grade 3-5 AE, n (%) 2 (10%) 6 (35%) P = 0.11 Conclusions Combination of clarithromycin, pioglitazone and metronomic chemotherapy is active in the > =2nd line treatment of NSCLC and warrants further investigations. Nivolumab did not induce any tumor response and was relatively toxic in this population. Novel treatment approaches are urgently needed for patients who previously received platinum-based chemotherapy for advanced squamous and non-squamous NSCLC (Funded by Anticancer Fund, EudraCT number 2014-004095-31). Clinical trial identification EudraCT: 2014-004095-31, Start Date: 2015-07-13. Legal entity responsible for the study Freistaat Bayern respresented by University of Regensburg represented by Kaufmannischer Direktor. Funding Anticancer Fund, Brussels, Belgium. Disclosure All authors have declared no conflicts of interest." @default.
• W2978219532 created "2019-10-10" @default.
• W2978219532 creator A5001678596 @default.
• W2978219532 creator A5012088874 @default.
• W2978219532 creator A5014089754 @default.
• W2978219532 creator A5016902031 @default.
• W2978219532 creator A5019811980 @default.
• W2978219532 creator A5021514540 @default.
• W2978219532 creator A5037052642 @default.
• W2978219532 creator A5040589443 @default.
• W2978219532 creator A5040663053 @default.
• W2978219532 creator A5041945240 @default.
• W2978219532 creator A5043156173 @default.
• W2978219532 creator A5053026695 @default.
• W2978219532 creator A5057268503 @default.
• W2978219532 creator A5061498879 @default.
• W2978219532 creator A5062484591 @default.
• W2978219532 creator A5063940692 @default.
• W2978219532 creator A5082034251 @default.
• W2978219532 creator A5082924805 @default.
• W2978219532 date "2019-10-01" @default.
• W2978219532 modified "2023-10-16" @default.
• W2978219532 title "Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)" @default.
• W2978219532 doi "https://doi.org/10.1093/annonc/mdz260.092" @default.
• W2978219532 hasPublicationYear "2019" @default.
• W2978219532 type Work @default.
• W2978219532 sameAs 2978219532 @default.
• W2978219532 citedByCount "1" @default.
• W2978219532 countsByYear W29782195322020 @default.
• W2978219532 crossrefType "journal-article" @default.
• W2978219532 hasAuthorship W2978219532A5001678596 @default.
• W2978219532 hasAuthorship W2978219532A5012088874 @default.
• W2978219532 hasAuthorship W2978219532A5014089754 @default.
• W2978219532 hasAuthorship W2978219532A5016902031 @default.
• W2978219532 hasAuthorship W2978219532A5019811980 @default.
• W2978219532 hasAuthorship W2978219532A5021514540 @default.
• W2978219532 hasAuthorship W2978219532A5037052642 @default.
• W2978219532 hasAuthorship W2978219532A5040589443 @default.
• W2978219532 hasAuthorship W2978219532A5040663053 @default.
• W2978219532 hasAuthorship W2978219532A5041945240 @default.
• W2978219532 hasAuthorship W2978219532A5043156173 @default.
• W2978219532 hasAuthorship W2978219532A5053026695 @default.
• W2978219532 hasAuthorship W2978219532A5057268503 @default.
• W2978219532 hasAuthorship W2978219532A5061498879 @default.
• W2978219532 hasAuthorship W2978219532A5062484591 @default.
• W2978219532 hasAuthorship W2978219532A5063940692 @default.
• W2978219532 hasAuthorship W2978219532A5082034251 @default.
• W2978219532 hasAuthorship W2978219532A5082924805 @default.
• W2978219532 hasBestOaLocation W29782195321 @default.
• W2978219532 hasConcept C121608353 @default.
• W2978219532 hasConcept C126322002 @default.
• W2978219532 hasConcept C126894567 @default.
• W2978219532 hasConcept C134018914 @default.
• W2978219532 hasConcept C143998085 @default.
• W2978219532 hasConcept C168563851 @default.
• W2978219532 hasConcept C2776256026 @default.
• W2978219532 hasConcept C2776409635 @default.
• W2978219532 hasConcept C2776694085 @default.
• W2978219532 hasConcept C2776962512 @default.
• W2978219532 hasConcept C2777180221 @default.
• W2978219532 hasConcept C2777701055 @default.
• W2978219532 hasConcept C2778384471 @default.
• W2978219532 hasConcept C2780030458 @default.
• W2978219532 hasConcept C555293320 @default.
• W2978219532 hasConcept C71924100 @default.
• W2978219532 hasConceptScore W2978219532C121608353 @default.
• W2978219532 hasConceptScore W2978219532C126322002 @default.
• W2978219532 hasConceptScore W2978219532C126894567 @default.
• W2978219532 hasConceptScore W2978219532C134018914 @default.
• W2978219532 hasConceptScore W2978219532C143998085 @default.
• W2978219532 hasConceptScore W2978219532C168563851 @default.
• W2978219532 hasConceptScore W2978219532C2776256026 @default.
• W2978219532 hasConceptScore W2978219532C2776409635 @default.
• W2978219532 hasConceptScore W2978219532C2776694085 @default.
• W2978219532 hasConceptScore W2978219532C2776962512 @default.
• W2978219532 hasConceptScore W2978219532C2777180221 @default.
• W2978219532 hasConceptScore W2978219532C2777701055 @default.
• W2978219532 hasConceptScore W2978219532C2778384471 @default.
• W2978219532 hasConceptScore W2978219532C2780030458 @default.
• W2978219532 hasConceptScore W2978219532C555293320 @default.
• W2978219532 hasConceptScore W2978219532C71924100 @default.
• W2978219532 hasLocation W29782195321 @default.
• W2978219532 hasOpenAccess W2978219532 @default.
• W2978219532 hasPrimaryLocation W29782195321 @default.
• W2978219532 hasRelatedWork W1986410768 @default.
• W2978219532 hasRelatedWork W2055244776 @default.
• W2978219532 hasRelatedWork W2115946307 @default.
• W2978219532 hasRelatedWork W2163547766 @default.
• W2978219532 hasRelatedWork W2348529436 @default.
• W2978219532 hasRelatedWork W2412747875 @default.
• W2978219532 hasRelatedWork W2413020017 @default.
• W2978219532 hasRelatedWork W2948845624 @default.
• W2978219532 hasRelatedWork W2955084311 @default.
• W2978219532 hasRelatedWork W8919293 @default.
• W2978219532 hasVolume "30" @default.
• W2978219532 isParatext "false" @default.
• W2978219532 isRetracted "false" @default.
• W2978219532 magId "2978219532" @default.

• next